US 12,343,390 B2
Recombinant biologically contained filovirus vaccine
Yoshihiro Kawaoka, Middleton, WI (US); and Peter J. Halfmann, Madison, WI (US)
Assigned to Wisconsin Alumni Research Foundation (WARF), Madison, WI (US)
Appl. No. 17/266,049
Filed by Wisconsin Alumni Research Foundation (WARF), Madison, WI (US)
PCT Filed Aug. 7, 2019, PCT No. PCT/US2019/045476
§ 371(c)(1), (2) Date Feb. 4, 2021,
PCT Pub. No. WO2020/033527, PCT Pub. Date Feb. 13, 2020.
Claims priority of provisional application 62/715,673, filed on Aug. 7, 2018.
Prior Publication US 2021/0290754 A1, Sep. 23, 2021
Int. Cl. A61K 39/12 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [C07K 16/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/6075 (2013.01); A61K 2039/70 (2013.01); C12N 2760/14134 (2013.01); C12N 2760/14152 (2013.01)] 18 Claims
 
1. A vaccine comprising an effective amount of a recombinant filovirus and one or more adjuvants comprising a saponin, wherein the genome of the recombinant filovirus contains a deletion of one or more nucleotides in a polynucleotide sequence for a viral protein corresponding to Ebola virus VP30, and wherein the deletion is effective to prevent expression of a functional viral protein corresponding to Ebola virus VP30 upon infection of a cell with the recombinant filovirus, wherein the genome further comprises a nucleotide sequence encoding a prophylactic or therapeutic heterologous gene product and wherein the nucleotide sequence is inserted into the filovirus genome at a site other than the site of the deletion in the polynucleotide or wherein the genome further comprises a nucleotide sequence encoding a prophylactic or therapeutic heterologous gene product and the nucleotide sequence replaces or is inserted into GP/sGP sequences or a portion thereof.